VYGR
Voyager Therapeutics, Inc.
Healthcare — Biotechnology
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Price History
Fundamentals
| Market Cap | $183.08M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.94 |
| EPS (TTM) | $-1.92 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -59.90% |
| ROE | -52.26% |
| Debt/Equity | 19.90 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $14.89 |
| Analysts | 9 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 39.6 |
| Beta | 1.27 |
| SMA 20 | $3.24 |
| SMA 40 | $3.40 |
| 52-Week High | $5.55 |
| 52-Week Low | $2.88 |
| 50-Day Avg | $3.47 |
| 200-Day Avg | $3.93 |
| Avg Volume | 640.3K |
| Volume | 416.5K |
Performance Analysis
NEUTRALVYGR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 05:07 UTC
Back to Screener Export Report